I thought CA implied that the " business decision" was based on the auditors finding that the clinical trial information not standing up to rigorous inspection. Now, it looks like the FDA might have convinced CA that they should be the judge of that. Who knows what is going on for sure? But, it is kind of fun guessing. We are, only, trying to make sense of the latest FDA requests for information.